# A Study to Evaluate the Pharmacokinetics of HSK16149 in Subjects With Renal Impairment

> **NCT05916573** · PHASE1 · COMPLETED · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** HSK16149

## Key facts

- **NCT ID:** NCT05916573
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-12
- **Primary completion:** 2023-02-27
- **Final completion:** 2023-04-26
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05916573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05916573, "A Study to Evaluate the Pharmacokinetics of HSK16149 in Subjects With Renal Impairment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05916573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*